Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx ®) as Pressurized Intraperitoneal Aerosol Chemotherapy
Background: Peritoneal carcinomatosis is a common metastatic pattern in ovarian, gastric, colorectal and appendiceal cancer; systemic chemotherapy is the current standard of care for peritoneal metastatic disease; however, in a subset of patients its beneficial effect remains questionable. More effective perioperative chemotherapy is needed.
Materials and Methods: PIPAC is a new treatment that applies chemotherapeutic drugs into the peritoneal cavity as an aerosol under pressure. It's a safe and feasible approach that improves local bioavailability of chemotherapeutic drugs as compared with conventional intraperitoneal chemotherapy. Till now the drugs used in PIPAC are Cisplatin, Doxorubicin and Oxaliplatin; as of yet, there are no in vivo data comparing different drug formulations and dosage schedules of PIPAC. Pegylated Liposomal Doxorubicin 1,5 mg/sm was aerosolized.
Results: pharmacokinetics analysis of 10 procedures performed with conventional Doxorubicin solution at the dose of 1.5 mg/m2 were compared to 15 procedures with the same dose of PLD. Significant differences between experimental groups were detected by one-way ANOVA followed by Bonferroni correction; a p value
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Appendix Cancer | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Colorectal Cancer | Drugs & Pharmacology | Eloxatin | Gastric (Stomach) Cancer | Gastroenterology | Ovarian Cancer | Ovaries | Peritoneal Cancer